Clinical Trial Update: Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety, adverse events, and pharmacokinetics of Azirkitug alone or in combination with Budigalimab, Bevacizumab, or Telisotuzumab A…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer Microsatellite-stable
• Esophageal Cancer
• Gastric Cancer
• Head and Neck Squamous Cell Carcinoma
• High-grade Serous Ovarian Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Azirkitug (Azirkitug)
• Bevacizumab (bevacizumab)
• Telisotuzumab Adizutecan (Telisotuzumab Adizutecan)
• budigalimab (budigalimab)

Snippet

Sponsor: AbbVie | Conditions: Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: RECRUITING